Show simple item record

 
dc.contributorHospital General de Granollers
dc.contributor.authorBala, Chandra
dc.contributor.authorPoyales, Francisco
dc.contributor.authorRuiz Mesa, Ramón
dc.contributor.authorMearza, Ali
dc.contributor.authorVarma, Devesh Kumar
dc.contributor.authorJasti, Srichand
dc.contributor.authorLemp-Hull, Jessie
dc.contributor.authorGuarro, Merce
dc.date.accessioned2022-04-07T11:58:27Z
dc.date.available2022-04-07T11:58:27Z
dc.date.issued2022-02-01
dc.identifier.citationBala C, Poyales F, Guarro M, Mesa RR, Mearza A, Varma DK, et al. Multicountry clinical outcomes of a new nondiffractive presbyopia-correcting IOL. J Cataract Refract Surg. 2022 Feb 1;48(2):136-143.
dc.identifier.issn0886-3350
dc.identifier.urihttps://hdl.handle.net/11351/7327
dc.descriptionLens Implantation Intraocular; Phacoemulsification; Prospective Studies
dc.description.abstractPurpose: To evaluate the effectiveness and safety of a new presbyopia-correcting intraocular lens (IOL) with a nondiffractive design, DFT015, compared with an aspheric monofocal IOL, SN60WF. Setting: 19 investigational sites in 4 countries: Australia, Canada, Spain, and the United Kingdom. Design: Prospective, randomized, parallel-group, controlled, assessor- and patient-masked clinical study. Methods: Participants aged ≥22 years with bilateral cataracts were randomized to DFT015 or SN60WF in a 5:4 ratio and masked until final postoperative follow-up at month 6. The primary effectiveness objective was superiority of DFT015 over SN60WF in mean monocular photopic distance-corrected intermediate visual acuity (DCIVA) at month 3. Secondary effectiveness objectives included noninferiority of DFT015 to SN60WF in mean monocular photopic corrected distance visual acuity (CDVA) and superiority in the mean monocular photopic distance-corrected near visual acuity (DCNVA) at month 3. Visual disturbances were assessed at month 6. Results: 282 patients were randomized to DFT015 (n = 159) or SN60WF (n = 123). All effectiveness objectives were achieved at month 3 in first eyes. For monocular photopic results in first eyes, DFT015 demonstrated superior mean DCIVA (least squares means of -0.139 logMAR in favor of DFT015, P < .001), noninferior mean CDVA (97.5% upper confidence limit [UCL] of the difference was <0.1 logMAR) and superior mean DCNVA (95% UCL of the difference was <0.0 logMAR) compared with SN60WF at month 6. DFT015 exhibited a similar visual disturbance profile to that of SN60WF. Conclusions: DFT015 provided superior intermediate and near vision and a similar visual disturbance profile compared with an aspheric monofocal IOL.
dc.language.isoeng
dc.publisherWolters Kluwer Health
dc.relation.ispartofseriesJournal of cataract and refractive surgery;48(2)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectLents intraoculars
dc.subjectFacoemulsificació
dc.subjectPròtesis
dc.subject.meshLens Implantation, Intraocular
dc.subject.meshPhacoemulsification
dc.subject.meshProspective Studies
dc.titleMulticountry clinical outcomes of a new nondiffractive presbyopia-correcting IOL
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1097/j.jcrs.0000000000000712
dc.subject.decsimplantación de lentes intraoculares
dc.subject.decsfacoemulsificación
dc.subject.decsestudios prospectivos
dc.relation.publishversionhttps://doi.org/10.1097/j.jcrs.0000000000000712
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Bala C] PersonalEyes, Sydney, Australia. [Poyales F] Miranza IOA Madrid Innova Ocular, Madrid, Spain. [Guarro M] OMIQ-Hospital General de Catalunya, Barcelona, Spain. Hospital General de Granollers, Granollers, Spain. [Mesa RR] Oftalvist CIO Jerez, Puerta del Sur Hospital, Cádiz, Spain. [Mearza A] Imperial College Healthcare NHS Trust & Ophthalmic Consultants of London, London, United Kingdom. [Varma DK] Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada. Prism Eye Institute, Oakville, Ontario, Canada. Trillium Health Partners, Mississauga, Ontario, Canada. [Jasti S, Lemp-Hull J] Alcon Laboratories, Inc., Fort Worth, Texas
dc.identifier.pmid34288635
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record